TRF-1101 Assessment in Sickle Cell Disease

Summary

This study is designed to assess the safety, tolerability, and activity of TRF-1101 on microvascular blood flow, vascular endothelial injury, and vasoocclusive pain associated with sickle cell disease.

Timeline

Start

2008-07

Primary completion

2009-05

Completion

2009-05

Outcome

Outcome not reported

Stopped: “Study was stopped due to perceived futility because the baseline pain score in first 40 patients was too low to be able demonstrate an improvement”

Drugs

Indications